Effects of thalidomide and baicalein on the proliferation, apoptosis and expression of CRBN protein in HEL cells

YAN Jingxiu; ZHAO Lidong

Journal of Xuzhou Medical University > 2017 > 37(9): 566-570.

YAN Jingxiu, ZHAO Lidong. Effects of thalidomide and baicalein on the proliferation, apoptosis and expression of CRBN protein in HEL cells[J]. Journal of Xuzhou Medical University, 2017, 37(9): 566-570.

Citation:

PDF (4567 KB)

Effects of thalidomide and baicalein on the proliferation, apoptosis and expression of CRBN protein in HEL cells

YAN Jingxiu,
ZHAO Lidong^,

Department of Hematology, Lianyungang Hospital Affiliated to Xuzhou Medical University, Lianyungang, Jiangsu 222000,China

More Information

Published Date: September 24, 2017

Graphical Abstract

Abstract

Abstract

ObjectiveTo observe the effects of thalidomide, baicalein and both on the proliferation, apoptosis and expression of cereblon (CRBN) protein in human erythroleukemia (HEL) cells. MethodsHEL cells were treated with thalidomide, baicalein or both for 48 h. The proliferation inhibitory rate was measured by CCK8 method. The apoptotic rate was detected by flow cytometry. The level of CRBN protein was measured by Western blot. ResultsThalidomide, baicalein and both could inhibit the proliferation of HEL cells, which were positively correlated with drug concentrations (r=0.991, r=0.989, and r=0.993, P<0.01). The combined use of thalidomide and baicalein produced remarkably enhanced effects against proliferation and stronger proapoptotic effects than thalidomide or baicalein alone (P<0.05). The level of CRBN protein in HEL cells was decreased after treatment with thalidomid for 48 h, which was negatively correlated with drug concentration (r=-0.975, P<0.01). The level of CRBN protein in HEL cells was decreased after treatment with baicalein for 48 h, which was positively correlated with drug concentration (r=0.973, P<0.01). ConclusionsThe combined use of thalidomide and baicalein can inhibit the proliferation but induce the apoptosis of HEL cells in a dose-dependent manner compared with thalidomide or baicalein alone, which may be associated with the role of baicalein to up-regulate the expression of the CRBN protein and enhance the sensitivity of HEL cells towards thalidomide.
- thalidomide,
- baicalein,
- human erythroleukemia cell,
- proliferation,
- apoptosis,
- CRBN protein

FullText(HTML)

References (19)

References

[1]	Tefferi A. Myelofibrosis with myeloid metaplasia [J].N Engl J Med, 2000,342(17):1255-1265.
[2]	Ribeiro J, Crispim ML, Vagnaldo FF, et al. Potential inhibitory effect of LASSBio-596, a new thalidomide hybrid, on inflammatory corneal angiogenesis in rabbits [J]. Ophthalmic Res, 2012,48(4):177-185.
[3]	Piura B, Medina L, Rabinovich A, et al. Thalidomide distinctly affected TNF-α, IL-6 and MMP secretion by an ovarian cancer cell line (SKOV-3) and primary ovarian cancer cells [J].Eur Cytokine Netw, 2013,24(3):122-129.
[4]	[4 ]Elliott MA, Mesa RA, Li CY,et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia [J]. Br J Haematol, 2002,117(2): 288-296.
[5]	Tefferi A, Cortes J, Verstovsek S, et al.Lenalidomide therapy in myelofibrosis with myeloid metaplasia [J]. Blood, 2006,108(4):1158-1164.
[6]	Begna KH, Pardanani A, Mesa R, et al. Long-term outcome of pomalidomide therapy in myelofibrosis [J]. Am J Hematol, 2012,87(1):66-68.
[7]	Broyl A, Kuiper R, van Duin M, et al.High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance [J]. Blood, 2013,121(4):624-627.
[8]	Zhu YX, Braggio E, Shi CX, et al.Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide[J]. Blood, 2011, 118(18): 4771-4779.
[9]	张锐波,何莉,黄赞,等.黄芩素与来那度胺联合诱导骨髓瘤细胞凋亡的协同作用及其机制研究[J].中华血液学杂志,2013，34(6):546-547.
[10]	Sderstrm M, Bolling A, Hammarstrm S, et al.Induction of leukotriene C4 synthase activity in differentiating human erythroleukemia cells[J].Biochem Biophys Res Commun, 1992, 189(2): 1043-1049.
[11]	Accardi A, Picollo A.CLC channels and transporters: proteins with borderline personalities [J]. Biochim Biophys Acta, 2010, 1798(8): 1457-1464.
[12]	Ito T, Ando H, Suzuki T, et al.Identification of a primary target of thalidomide teratogenicity[J]. Science, 2010, 327 (5971): 1345-1350.
[13]	Lu G, Middleton RE, Sun HH, et al.The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins[J]. Science, 2014,343(6168): 305-309.
[14]	Krnke J, Udeshi ND, Narla A,et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myelomacells[J]. Science, 2014, 343(6168): 301-305.
[15]	Fang J, Liu XN, Bolanos L,et al.A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes[J]. Nat Med, 2016, 22(7): 727-734.
[16]	Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?[J].Leuk Res, 2013, 37(2): 214-220.
[17]	吴小谢,薛连国,赵利东,等.干扰素联合沙利度胺对HEL细胞凋亡及JAK2V617F突变基因表达的影响[J]. 中国实验血液学杂志,2016, 24(4):998-1002.
[18]	Tefferi A, Lasho TL, Mesa RA,et al. Lenalidomide therapy in del (5) (q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions[J]. Leukemia, 2007, 21(8): 1827-1828.
[19]	周凝溪. Cereblon在慢性骨髓增殖性肿瘤中表达的临床意义[D].石家庄：河北医科大学,2015.

Cited By

Get Citation

PDF

XML

Article views (1902) PDF downloads (0)

Turn off MathJax

Article Contents

Abstract

References

Effects of thalidomide and baicalein on the proliferation, apoptosis and expression of CRBN protein in HEL cells

Abstract

References

Catalog

Export File

Citation

Format

Content